168 related articles for article (PubMed ID: 29969558)
1. Dendrimer Scaffold for the Amplification of In Vivo Pretargeting Ligations.
Cook BE; Membreno R; Zeglis BM
Bioconjug Chem; 2018 Aug; 29(8):2734-2740. PubMed ID: 29969558
[TBL] [Abstract][Full Text] [Related]
2. Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate.
Cook BE; Adumeau P; Membreno R; Carnazza KE; Brand C; Reiner T; Agnew BJ; Lewis JS; Zeglis BM
Bioconjug Chem; 2016 Aug; 27(8):1789-95. PubMed ID: 27356886
[TBL] [Abstract][Full Text] [Related]
3. Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.
Zeglis BM; Brand C; Abdel-Atti D; Carnazza KE; Cook BE; Carlin S; Reiner T; Lewis JS
Mol Pharm; 2015 Oct; 12(10):3575-87. PubMed ID: 26287993
[TBL] [Abstract][Full Text] [Related]
4. Dual Radionuclide Theranostic Pretargeting.
Keinänen O; Brennan JM; Membreno R; Fung K; Gangangari K; Dayts EJ; Williams CJ; Zeglis BM
Mol Pharm; 2019 Oct; 16(10):4416-4421. PubMed ID: 31483993
[TBL] [Abstract][Full Text] [Related]
5. Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy.
Membreno R; Keinänen OM; Cook BE; Tully KM; Fung KC; Lewis JS; Zeglis BM
Mol Pharm; 2019 May; 16(5):2259-2263. PubMed ID: 30912951
[TBL] [Abstract][Full Text] [Related]
6. Harnessing
Keinänen O; Fung K; Brennan JM; Zia N; Harris M; van Dam E; Biggin C; Hedt A; Stoner J; Donnelly PS; Lewis JS; Zeglis BM
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28316-28327. PubMed ID: 33106429
[TBL] [Abstract][Full Text] [Related]
7. Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma.
Membreno R; Cook BE; Fung K; Lewis JS; Zeglis BM
Mol Pharm; 2018 Apr; 15(4):1729-1734. PubMed ID: 29502416
[TBL] [Abstract][Full Text] [Related]
8. Pretargeted PET of Osteodestructive Lesions in Dogs.
Maitz CA; Delaney S; Cook BE; Genady AR; Hoerres R; Kuchuk M; Makris G; Valliant JF; Sadeghi S; Lewis JS; Hennkens HM; Bryan JN; Zeglis BM
Mol Pharm; 2022 Sep; 19(9):3153-3162. PubMed ID: 35635337
[TBL] [Abstract][Full Text] [Related]
9. Manipulating the In Vivo Behaviour of
Imberti C; Adumeau P; Blower JE; Al Salemee F; Baguña Torres J; Lewis JS; Zeglis BM; Terry SYA; Blower PJ
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098299
[TBL] [Abstract][Full Text] [Related]
10. Trans-cyclooctene tag with improved properties for tumor pretargeting with the diels-alder reaction.
Rossin R; van Duijnhoven SM; Läppchen T; van den Bosch SM; Robillard MS
Mol Pharm; 2014 Sep; 11(9):3090-6. PubMed ID: 25077373
[TBL] [Abstract][Full Text] [Related]
11. A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer.
Adumeau P; Carnazza KE; Brand C; Carlin SD; Reiner T; Agnew BJ; Lewis JS; Zeglis BM
Theranostics; 2016; 6(12):2267-2277. PubMed ID: 27924162
[TBL] [Abstract][Full Text] [Related]
12. A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry.
Zeglis BM; Sevak KK; Reiner T; Mohindra P; Carlin SD; Zanzonico P; Weissleder R; Lewis JS
J Nucl Med; 2013 Aug; 54(8):1389-96. PubMed ID: 23708196
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
14. Site-Specific Photoaffinity Bioconjugation for the Creation of
Delaney S; Nagy Á; Karlström AE; Zeglis BM
Mol Imaging Biol; 2023 Dec; 25(6):1104-1114. PubMed ID: 37052759
[TBL] [Abstract][Full Text] [Related]
15. Harnessing the bioorthogonal inverse electron demand Diels-Alder cycloaddition for pretargeted PET imaging.
Reiner T; Lewis JS; Zeglis BM
J Vis Exp; 2015 Feb; (96):e52335. PubMed ID: 25742199
[TBL] [Abstract][Full Text] [Related]
16. Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers.
Meyer JP; Tully KM; Jackson J; Dilling TR; Reiner T; Lewis JS
Bioconjug Chem; 2018 Feb; 29(2):538-545. PubMed ID: 29378403
[TBL] [Abstract][Full Text] [Related]
17. DOTA-tetrazine probes with modified linkers for tumor pretargeting.
Läppchen T; Rossin R; van Mourik TR; Gruntz G; Hoeben FJM; Versteegen RM; Janssen HM; Lub J; Robillard MS
Nucl Med Biol; 2017 Dec; 55():19-26. PubMed ID: 29028502
[TBL] [Abstract][Full Text] [Related]
18. (18)F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry.
Meyer JP; Houghton JL; Kozlowski P; Abdel-Atti D; Reiner T; Pillarsetty NV; Scholz WW; Zeglis BM; Lewis JS
Bioconjug Chem; 2016 Feb; 27(2):298-301. PubMed ID: 26479967
[TBL] [Abstract][Full Text] [Related]
19. Antibody PEGylation in bioorthogonal pretargeting with trans-cyclooctene/tetrazine cycloaddition: in vitro and in vivo evaluation in colorectal cancer models.
Rondon A; Ty N; Bequignat JB; Quintana M; Briat A; Witkowski T; Bouchon B; Boucheix C; Miot-Noirault E; Pouget JP; Chezal JM; Navarro-Teulon I; Moreau E; Degoul F
Sci Rep; 2017 Nov; 7(1):14918. PubMed ID: 29097747
[TBL] [Abstract][Full Text] [Related]
20. Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.
Houghton JL; Zeglis BM; Abdel-Atti D; Sawada R; Scholz WW; Lewis JS
J Nucl Med; 2016 Mar; 57(3):453-9. PubMed ID: 26471693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
